138 related articles for article (PubMed ID: 27663525)
1. Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis.
Nakano K; Motoi N; Tomomatsu J; Gokita T; Ae K; Tanizawa T; Matsumoto S; Takahashi S
BMC Cancer; 2016 Sep; 16(1):750. PubMed ID: 27663525
[TBL] [Abstract][Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
3. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series.
Verschoor AJ; Gelderblom H
Clin Sarcoma Res; 2014; 4():14. PubMed ID: 25302110
[TBL] [Abstract][Full Text] [Related]
4. Pneumothorax in lung metastasis of advanced soft tissue sarcoma patients treated with oral pazopanib.
Sarkar S; Mishra PK; Mukhopadhyay S; Sen S; Biswas B
Indian J Cancer; 2023 Sep; ():. PubMed ID: 38090966
[TBL] [Abstract][Full Text] [Related]
5. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
Sabath B; Muhammad HA; Balagani A; Ost DE; Vakil E; Ahmed T; Vial MR; Grosu HB
BMC Cancer; 2018 Oct; 18(1):937. PubMed ID: 30285733
[TBL] [Abstract][Full Text] [Related]
6. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib in rare histologies of metastatic soft tissue sarcoma.
Kataria B; Sharma A; Biswas B; Bakhshi S; Pushpam D
Ecancermedicalscience; 2021; 15():1281. PubMed ID: 34824604
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma - A Single Institute Analysis.
Wang X; Nakano K; Shiga T; Ohmoto A; Oyakawa T; Ebihara A; Sato Y; Fukuda N; Nishizawa M; Urasaki T; Ono M; Yunokawa M; Tomomatsu J; Takahashi S
Circ J; 2024 Jan; 88(2):228-233. PubMed ID: 35314578
[TBL] [Abstract][Full Text] [Related]
9. Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
Aiba H; Kimura H; Yamada S; Okamoto H; Hayashi K; Miwa S; Kawaguchi Y; Saito S; Sakai T; Tatematsu T; Nakanishi R; Murakami H
PLoS One; 2021; 16(7):e0254866. PubMed ID: 34270626
[TBL] [Abstract][Full Text] [Related]
10. Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature.
Nakahara Y; Fukui T; Katono K; Nishizawa Y; Okuma Y; Ikegami M; Sasaki J; Masuda N
Case Rep Oncol; 2017; 10(1):333-338. PubMed ID: 28559816
[TBL] [Abstract][Full Text] [Related]
11. Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders.
Nakano K; Funauchi Y; Hayakawa K; Tanizawa T; Ae K; Matsumoto S; Takahashi S
J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30626115
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?].
Agrafiotis AC; Prieto M; Verhaeghe JL; Siat J; Grosdidier G; Rios M
Rev Pneumol Clin; 2016 Oct; 72(5):293-295. PubMed ID: 27561973
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
14. [Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma].
Kanno N; Nakahashi K; Shiikawa M; Endo M; Numahata K; Shiono S
Gan To Kagaku Ryoho; 2021 Jul; 48(7):975-977. PubMed ID: 34267040
[TBL] [Abstract][Full Text] [Related]
15. Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment.
Takada K; Murase K; Nakamura H; Hayasaka N; Arihara Y; Iyama S; Ikeda H; Emori M; Sugita S; Nakamura K; Miyanishi K; Kobune M; Kato J
Intern Med; 2019 Oct; 58(20):3009-3012. PubMed ID: 31243217
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada.
Delea TE; Amdahl J; Nakhaipour HR; Manson SC; Wang A; Fedor N; Chit A
Curr Oncol; 2014 Dec; 21(6):e748-59. PubMed ID: 25489263
[TBL] [Abstract][Full Text] [Related]
19. A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment.
Çelik B; Sürücü ZP; Yılmaz V; Çelik HK
Turk Thorac J; 2018 Jan; 19(1):49-51. PubMed ID: 29404187
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib and soft-tissue sarcomas. Too toxic.
Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
